TENDER NO. BMSIC/DRUGS/18-04						
Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids						
Company Name Scot Edil Pharmacia Ltd_____ Total Number of Pages Submitted in bid documents_____						
Sl. No	**SBD clause serial No**	**Descrption of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List**	**Document/ fees submission status (Yes/ No)**	**Page number**	**Do the provided documents meet the eligibility criteria ? (Yes/ No)**	**Remarks**
1	3. (a)	**Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft** drawn in Favor of "Managing Director, Bihar Medical Services and Infrastructure Corporation Limited" payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	yes	2	yes	
2	3.(b)	Bidder are required to submit **Earnest Money Deposit in the form of Demand Draft / Bank Guarantee** drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna as follows:- Upto 5 drugs- Rs1,00,000/- (One Lakh only), for 6 to 10 drugs- Rs 2,00,000/- (Two Lakh only), for 11 to 20 drugs- Rs 3,00,000/-(Three Lakh only) and for More than 20 drugs Rs 5,00,000/- (Five Lakh only)	yes	51	yes	
3	3.(c)	Documentary evidence of the **constitution of the company/ firm/ Proprietorship such as Memorandum and Articles of Association, Partnership Deed** etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	yes	116-64	yes	
4	3.(d)	The **details of Bidder** Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	yes	119	yes	
5	3.(e)	**Power of Attorney or Resolution of Board** by which the **authorised signatory** has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. **Format to be used.**	yes	61-62	yes	
6	3.(l)	Copies of the **Audited Balance Sheet and Profit and Loss statement** showing details of their annual average turnover not less than **25 Crores** for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). **Self-attested copies** are to be submitted.	yes	60-55	yes	

Chandan kumar Jha
14/7/18

7	3.(m)	Copy of **Income Tax Return for any three of last four Consecutive Assessment years** should be submitted **(self-attested)**.	**yes**	**46-44**	**yes**	
8	3.(p)	**Copy of PAN Card of the bidder company should be submitted (self-attested).**	**yes**	**3**	**yes**	
9	3.(q)	**Copy of certificate of valid Sales Tax/VAT and GST registration of the bidder company should be submitted (self-attested).**	**yes**	**50**	**yes**	

Chandan Kumar
14/7/18

TENDER NO. BMSIC/DRUGS/18-04						
Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids						
Company Name: M/s Scott Edil Pharmecia Ltd.				**Total Number of Pages Submitted in bid documents: 160**		
Sl. No	**SBD Clause serial No**	**Descrption of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List**	**Document submission status (Yes/ No)**	**Page Number as numbered by BMSICL**	**Do the provided documents meet the eligibility criteria ? (Yes/ No)**	**Remarks**
1	3.(d)	The **details of Bidder** Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	119	Yes	Managing Director address not mentioned in attached document.
2	3.(e)	**Power of Attorney or Resolution of Board** by which the **authorised signatory** has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. **Format to be used.**	Yes	61	Yes	
3	3.(f)	Minimum **three years old valid Manufacturing License of the product quoted with latest license renewal certificate**.	Yes	39-41	Yes	
4		**Approved product list as per the license issued for quoted drugs for minimum three years.**	Yes	13-38	NO	For NIT sl. No. 3 first Approval date in generic name is 14th Jan 2016.
5		**Manufacturing License** along with approved product list must be **valid till the last date of the submission of tender.**	Yes	13-41	Yes	
6		In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.	NA	NA	NA	
7		**Market standing certificate & Manufacturing certificate** issued by the Licensing Authority as a Manufacturer **for each drug quoted** for the **last 3 years** (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation).	Yes	5 to 12	No	Quoted NIT Sl. No. - 26, 118, 120 & 205 Market standing Certificate & Manufacturing Certificate not attached.
8		If permission in **Form 46 (For manufacturers) / Form 45 (For Importers) from DCGI** has been obtained, then the **3 years manufacturing/ Import & Market standing clause will be relaxed**. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.	NA	NA	NA	

14.7.18

9		For **all regulated products,** the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	**NA**	**NA**	**NA**	
10		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable	**NA**	**NA**	**NA**	
		NOTE: Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	**Yes**	**Page no. 39 to 41**	**Yes**	
11	**3.(g)**	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	**NA**	**NA**	**NA**	
12	**3.(h)**	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. **Self-attested copies** are to be submitted.	**Yes**	**Page no. 05 to 12**	**No**	**For NIT Sl. No. 26, 118, 120 & 205 MSC in Generic name not attached**
13	**3.(i)**	Non Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted. It should be not more than one year old. **Self-attested copies** are to be submitted. For Surgicals In case of Non-Drug item "the bidder shall submit an affidavit on Non-Judicial stamp paper stating that the quoted product is not covered under Drugs & Cosmetics Act."	**Yes**	**Page no. 04**	**Yes**	
14	**3.(j)**	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule-'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. **Self-attested copies** are to be submitted.	**Yes**	**Page no. 01**	**Yes**	

R.K.Jain 14.7.18.

15	**3.(k)**	**Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department** highlighting the **quoted product** section. **Self-attested copies** are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production(Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	**Yes**	**Page no. 52**	**Yes**	Certificate was issued on 12th Sept. 2011.
16	**3.(n)**	**The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.**	**Yes**	**Page no. 63**	**Yes**	Whether Blacklisted or not No , As per attached document.
17	**3.(o)**	**List of item quoted in prescribed format as per Annexure-III duly signed.**	**Yes**	**Page no. 42**	**Yes**	
18	**5.(k)**	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per **Annexure-IV.**	**Yes**	**Page no. 120**	**Yes**	
19	**5.(l)**	**Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.**	**NO**			**Not attached**
20	**7.(c)**	**Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.**	**Yes**	**Page no. 61**	**Yes**	
21	**10.(c)**	**If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.**	**Yes**	**Page no. 47**	**Yes**	
22	**Corrigendum point**	**A Notarized affidavit on a Rs 100/- Non-Judicial Stamp Paper representing that the offered price is the lowest price as compared to the Rates provided to their respective Distributors/ Dealers/ Wholesalers/ Carrying and Forwarding Agents/ Authorized depot sales point in the State of Bihar.**	**Yes**	**Page no. 121**	**Yes**	

14.7.18.

TENDER NO. BMSIC/DRUGS/18-04

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name: M/s Scott Edil Pharmacia Ltd. **Total number of pages submitted in bid documents: 160**

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic Name	
1	3	Albendazole Tablet IP	1. EXYT - 400 2. Albendazole Tablet IP	IP/400mg.	IP/400mg.	10X10	Not mentioned	Tablet	Tablet	Pg. 38 Brand - 11/07/2011, **Pg. 24 Generic 14/01/2016**	29/05/2020	Brand & Generic Name	Yes Generic Page. - 12
2	24	Azithromycin Tablet IP	1. AZISCOT - 250 2. Azithromycin Tablet IP	IP/250mg.	IP/250mg.	10X6	Not mentioned	Tablet	Tablet	Pg. 37 Brand - 18/06/2010 Pg. 22 Generic 01/06/2015	29/05/2020	Brand & Generic Name	Yes Generic Page. - 11
3	25	Azithromycin Tablet IP	1. AZISCOT - 500 2. Azithromycin Tablet IP	IP/500mg.	IP/500mg.	10X6	Not mentioned	Tablet	Tablet	Pg. 37 Brand - 18/06/2010 Pg. 22 Generic 01/06/2015	29/05/2020	Brand & Generic Name	Yes Generic Page. - 11
4	26	Azithromycin Oral Suspension IP	1. AZISCOT - 200 2. Azithromycin Oral Suspension IP	IP/200mg/5ml	IP/200mg	15ml. Bottle	Not mentioned	Suspension	Suspension	Pg. 36 Brand - 11/10/2010 Pg. 23 Generic 01/06/2015	29/05/2020	Brand & Generic Name	**No Not Attached**
5	56	Diclofanac Sodium Tablets IP	1. VOLIGESIC 2. Diclofanac Sodium Tablets IP	IP/50mg.	IP/50mg.	10X10	Not mentioned	Tablet Gastro Resistant	Tablet	Pg. 35 Brand - 02/07/2012 Pg. 21 Generic 02/11/2015	29/05/2020	Brand & Generic Name	Yes Generic Page. - 10
6	57	Diclofanac Sodium Injection IP (Diclofanac Injection IP)	Diclofanac Injection IP (Not for vet. Use)	IP/25mg/ml	IP/25mg/ml	3ml. Ampoule	Not mentioned	Ampoule	Ampoule	Pg. 34 31-12-2012	29/05/2020	Generic Name	Yes Generic Page. - 08
7	65	Dexamethasone Sodium Phosphate Injection IP	1. ZYDEXA 2. Dexamethasone Sodium Phosphate Injection IP	IP/4mg/ml	IP/4mg/ml	2ml Vial	Not mentioned	Vial	Vial	Pg. 33 Brand - 09/09/2010 Pg. 19 Generic 01/06/2015	29/05/2020	Brand & Generic Name	Not submitted ingeneric name
8	118	Levofloxacin Tablet IP	1. OMFLOX - 250 2. Levofloxacin Tablet IP	250mg.	IP/250mg.	10X10	Not mentioned	Tablet	Tablet	Pg. 32 Brand - 23/10/2010 Pg. 18 Generic 14/01/2016	29/05/2020	Brand & Generic Name	**No Not Attached**

14.7.18

9	119	Levofloxacin Tablet IP	1. OMFLOX - 500 2. Levofloxacin Tablet IP	500mg.	IP/500mg.	10X10	Not mentioned	Tablet	Tablet	Pg. 32 Brand - 23/10/2010 **Pg. 18 Generic 14/01/2016**	29/05/2020	Brand & Generic Name	**No Not Attached**
10	120	Levofloxacin Tablet IP	1. OMFLOX - 750 2. Levofloxacin Tablet IP	750mg.	IP/750mg.	10X10	Not mentioned	Tablet	Tablet	Pg. 32 Brand - 23/10/2010 **Pg. 28 Generic 14/01/2016**	29/05/2020	Brand & Generic Name	**No Not Attached**
11	126	Linezolid IP	1. ZYGOZOLID - 600 2. Linezolid IP 600mg	IP/600mg.	IP/600mg.	10X10	Not mentioned	Tablet	Tablet	Pg. 31 Brand - 29/03/2012 **Pg. 17 Generic 23/09/2016**	29/05/2020	Brand & Generic Name	Yes Generic Page. - 05
12	144	Methyl Prednisolone Acetate Injection 500mg	1. EDIPRED - 500 2. Methyl Prednisolone **Sodium Succinate** Injection 500mg USP	40mg/ml	USP/500mg.	Vial	Not mentioned	Powder for Injection	**Not mentioned**	Pg. 30 Brand - 01/11/2011 Pg. 16 Generic 01/06/2015	29/05/2020	Brand & Generic Name	Yes Generic Page. - 05
13	145	Methyl Prednisolone Acetate Injection 1000mg	1. EDIPRED - 1000 2. Methyl Prednisolone **Sodium Succinate** Injection 1000mg USP	40mg/ml	USP/1000mg.	Vial	Not mentioned	Powder for Injection	**Not mentioned**	Pg. 29 Brand - 04/05/2011 Pg. 16 Generic 01/06/2015	29/05/2020	Brand & Generic Name	Yes Generic Page. - 07
14	166	Ofloxacin Tablet IP	1. ENDIE 2. Ofloxacin Tablet IP	200mg.	IP/200mg	10X10	Not mentioned	Tablet	Tablet	Pg. 37 Brand - 18/06/2010 **Pg. 24 Generic 14/01/2016**	29/05/2020	Brand & Generic Name	Yes Generic Page. - 09
15	184	Paracetamol Oral Suspension IP	Paracetamol Oral Suspension IP	125mg/5ml	IP/125mg.	**15ml.**	Not mentioned	**Drop.**	**Suspension**	Pg. 28 22/11/2013	29/05/2020	Generic Name	Yes Generic Page. - 05
16	187	Pemethrin Cream	1. PERFACT 2. Pemethrin Cream	5%w/w	5% IP	60gm.	Not mentioned	Ointment	Cream	Pg. 27 Brand - 14/06/2011 Pg. 15 Generic 14/06/2012	29/05/2020	Brand & Generic Name	Yes Generic Page. - 05
17	195	Silver Sulphadiazine	Silver Sulphadiazine Cream USP	1%w/v	1% USP	25gm. Tube	Not mentioned	Cream	Cream	Pg. 26 02/07/2013	29/05/2020	Generic Name	Yes Generic Page. - 06
18	205	Telmisartan Tablet IP	1. HEARTEL - 20 2. Telmisartan Tablet IP - 20 mg	40mg.	**IP/20mg.**	10X10	Not mentioned	Tablet	Tablet	Pg. 25 Brand - 12/04/2012 **Pg. 13 Generic Date is not Cleared**	29/05/2020	Brand & Generic Name	**No Not Attached**

Note :- As per *NIT Sl. No. 205 strength is 40 mg IP but approval for Brand and Generic is 20 mg, on page no.-13 date is not clear.

*** NIT Sl. No. 26, 118, 120 and 205 Manufacturing and Marketing Certificate not attached in Bid.**

*** NIT Sl. No. 144 and 145 Dosage form as per NIT not mentioned in as per approval in Pharmacopoeial specification/strength is not cleare (as 40mg/ml).**

14.2.18.

TENDER NO. BMSIC/DRUGS/18-04

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name: M/s Scott Edil Pharmacia Ltd. **Total number of pages submitted in bid documents: 160**

Sheet for verification of licence details

Sl. No	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	3	Albendazole Tablet IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2005	29-05-2020	23-01-2018	22-01-2020
2	24	Azithromycin Tablet IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2005	29-05-2020	23-01-2018	22-01-2020
3	25	Azithromycin Tablet IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2005	29-05-2020	23-01-2018	22-01-2020
4	26	Azithromycin Oral Suspension IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2005	29-05-2020	23-01-2018	22-01-2020
5	56	Diclofanac Sodium Tablets IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2005	29-05-2020	23-01-2018	22-01-2020
6	57	Diclofanac Sodium Injection IP (Diclofanac Injection IP)	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
7	65	Dexamethasone Sodium Phosphate Injection IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
8	118	Levofloxacin Tablet IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020

14.07.18.

9	119	Levofloxacin Tablet IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
10	120	Levofloxacin Tablet IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
11	126	Linezolid IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
12	144	Methyl Prednisolone Acetate Injection 500mg	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
13	145	Methyl Prednisolone Acetate Injection 1000mg	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
14	166	Ofloxacin Tablet IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
15	184	Paracetamol Oral Suspension IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
16	187	Pemethrin Cream	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
17	195	Silver Sulphadiazine	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020
18	205	Telmisartan Tablet IP	25 or 28	MNB/05/138 & MNB/05/139	NA	NA	30-05-2015	29-05-2020	23-01-2018	22-01-2020

Note: - Assisted in technical evaluation in reference to letter No-559(15), dated 26.6.2018 on the basis of documents provided by BMSICL in checklist-II, III & IV. Provided checklist compiled with due deligence and care. Inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time, if any discrepancies are observed, for rectification.

N. K. Sharma
14.07.18.